Skip to main content
TNGX
NASDAQ Life Sciences

Tango Therapeutics Posts Q2 2026 Loss, Narrows Pipeline, and Reveals New Insider Trading Plans

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$28.05
Mkt Cap
$4.505B
52W Low
$6.25
52W High
$34.39
52W Position info
349% above low
Off High info
18% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

TNGX has more than doubled off its 52-week low of $6.25.

Summary

Tango Therapeutics reported a $55.3M Q2 loss, ended with $1.0B in cash after a June equity raise, and is deprioritizing two early-stage programs to focus on its lead oncology assets. Two officers adopted pre-arranged stock trading plans.


Key Events · Earnings and Guidance · TNGX

  • Q2 2026 Net Loss Widens

    Driven by increased R&D and G&A expenses, including higher stock-based compensation, the net loss reached $55.3 million, up from $38.9 million in Q2 2025.

  • Cash Runway Extended

    Following a $690 million gross proceeds equity offering in June 2026, the quarter ended with $1.0 billion in cash and marketable securities, providing runway well beyond 12 months.

  • Pipeline Reprioritization

    To focus resources on lead PRMT5 inhibitors vopimetostat and TNG456, the company deprioritized the TNG260 (CoREST inhibitor) and TNG961 (undisclosed target) programs.

  • Insider Trading Plans Adopted

    President of R&D Adam Crystal adopted a 10b5-1 plan to sell up to 210,000 shares, while Principal Accounting Officer Jessica Newcomb adopted a plan to sell up to 68,655 shares.


Analysis · TNGX · Life Sciences

A $55.3 million net loss for Q2 2026 reflects higher R&D and G&A spending at Tango Therapeutics. Bolstered by a $690 million equity raise in June, the company closed the quarter with $1.0 billion in cash. To sharpen its focus on lead PRMT5 inhibitors, management is deprioritizing the TNG260 and TNG961 programs. Additionally, two officers adopted 10b5-1 trading plans during the quarter, signaling potential future insider sales.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TNGX was trading at $28.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $6.25 to $34.39. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TNGX - Latest Insights

TNGX
Nov 09, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $21.82
Real-time Price: $25.26 info
Change: +$3.44 (+16%) info
Market Cap: $4.321B info
TNGX
Oct 23, 2026, 7:01 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $29.13
Real-time Price: $25.26 info
Change: -$3.87 (-13%) info
Market Cap: $4.321B info
TNGX
Oct 23, 2026, 6:36 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $31.85
Real-time Price: $25.26 info
Change: -$6.59 (-21%) info
Market Cap: $4.321B info
TNGX
Oct 23, 2026, 6:30 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $32.06
Real-time Price: $25.26 info
Change: -$6.80 (-21%) info
Market Cap: $4.321B info
TNGX
Aug 11, 2026, 5:10 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $26.45
Real-time Price: $25.26 info
Change: -$1.19 (-4%) info
Market Cap: $4.321B info